HK1220450A1 - 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品 - Google Patents
治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品 Download PDFInfo
- Publication number
- HK1220450A1 HK1220450A1 HK16108426.9A HK16108426A HK1220450A1 HK 1220450 A1 HK1220450 A1 HK 1220450A1 HK 16108426 A HK16108426 A HK 16108426A HK 1220450 A1 HK1220450 A1 HK 1220450A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- phenazine
- phenothiazine
- oxidative stress
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/838,372 US20140275045A1 (en) | 2013-03-15 | 2013-03-15 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US13/838,372 | 2013-03-15 | ||
| PCT/US2014/029811 WO2014145119A1 (en) | 2013-03-15 | 2014-03-14 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1220450A1 true HK1220450A1 (zh) | 2017-05-05 |
Family
ID=50680171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16108426.9A HK1220450A1 (zh) | 2013-03-15 | 2014-03-14 | 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140275045A1 (https=) |
| EP (1) | EP2970151A1 (https=) |
| JP (1) | JP2016514697A (https=) |
| CA (1) | CA2906154A1 (https=) |
| HK (1) | HK1220450A1 (https=) |
| WO (1) | WO2014145119A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| WO2016133995A1 (en) * | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| US10364227B2 (en) | 2015-02-17 | 2019-07-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US12570622B2 (en) | 2016-08-25 | 2026-03-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| WO2018039487A1 (en) * | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| JP6958860B2 (ja) | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE840115L (en) * | 1983-01-21 | 1984-07-21 | Merck Frosst Canada Inc | Phenothiazine derivatives and analogs |
| US4667032A (en) * | 1983-01-21 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazone derivatives and analogs |
| US4548927A (en) * | 1983-05-25 | 1985-10-22 | Eaton John W | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics |
| JPS60209520A (ja) * | 1984-03-19 | 1985-10-22 | メルク エンド カムパニー インコーポレーテツド | リポキシゲナーゼ阻害剤の細胞保護的使用 |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| CA2830581A1 (en) * | 2011-04-04 | 2012-10-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
-
2013
- 2013-03-15 US US13/838,372 patent/US20140275045A1/en not_active Abandoned
-
2014
- 2014-03-14 WO PCT/US2014/029811 patent/WO2014145119A1/en not_active Ceased
- 2014-03-14 JP JP2016503226A patent/JP2016514697A/ja active Pending
- 2014-03-14 HK HK16108426.9A patent/HK1220450A1/zh unknown
- 2014-03-14 EP EP14722468.7A patent/EP2970151A1/en not_active Withdrawn
- 2014-03-14 CA CA2906154A patent/CA2906154A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2970151A1 (en) | 2016-01-20 |
| JP2016514697A (ja) | 2016-05-23 |
| CA2906154A1 (en) | 2014-09-18 |
| WO2014145119A1 (en) | 2014-09-18 |
| US20140275045A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220450A1 (zh) | 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品 | |
| HK1220449A1 (zh) | 治疗氧化应激障碍的试卤灵衍生物 | |
| HK1220451A1 (zh) | 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物 | |
| HK1223369A1 (zh) | 用於治疗氧化应激障碍的羧酸衍生物 | |
| WO2009111576A3 (en) | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | |
| EP3413852A4 (en) | METHOD, COMPOSITIONS AND DEVICES FOR TREATING PSORIASIS BY PHOTOTHERAPY | |
| EP3099380A4 (en) | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders | |
| EP3119913A4 (en) | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring | |
| EP3233091A4 (en) | Hypochlorous acid formulations and methods for treating skin conditions | |
| EP3139939A4 (en) | Compositions and methods for treating skin and mucous membrane diseases | |
| EP3347000A4 (en) | METHODS OF TREATING DISORDERS AND SKIN DISORDERS USING HAPTENES | |
| EP3377090A4 (en) | Methods for treatment of bile acid-related disorders | |
| EP3503906A4 (en) | METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH BILAR ACIDS | |
| EP3096617A4 (en) | Compositions and methods for treating ocular diseases | |
| EP3240612A4 (en) | Methods of treating retinal diseases | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| MX2021009340A (es) | Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5- trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida. | |
| HK1249051A1 (zh) | 治疗脑肿瘤的方法 | |
| EP3554505A4 (en) | METHODS FOR TREATMENT OF EYE DISEASES | |
| EP3554502A4 (en) | METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY | |
| EP3104852A4 (en) | Compositions and methods for treating aging and age-related diseases and symptoms | |
| EP3253401A4 (en) | Method of treating diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| EP3240577A4 (en) | Methods and compositions for treating brain diseases | |
| EP3217974A4 (en) | Method for treating, preventing, or reducing the risk of skin infection |